Trial reportAnnals of surgery2005
A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.
Trial report in Annals of surgery, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- The mCancers · 2023Article
- Biological functions and research progress of eIF4E.Frontiers in oncology · 2023Review
- Expression of eIF4E Gene in Glioma and Its Sensitivity to Oxidative Stress.Oxidative medicine and cellular longevity · 2022Article
- Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy.Oncotarget · 2017Article
- Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.Frontiers in oncology · 2017Review
- The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.Breast cancer (Dove Medical Press) · 2017Article
- Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3.Oncogene · 2015Article
- Targeting translation initiation in breast cancer.Translation (Austin, Tex.) · 2014Review
- Exposure to excess estradiol or leptin during pregnancy increases mammary cancer risk and prevents parity-induced protective genomic changes in rats.Cancer prevention research (Philadelphia, Pa.) · 2013Article
- Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma.World journal of gastroenterology · 2012Article
- The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival.Cancer biology & therapy · 2010Article
- Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?Leukemia & lymphoma · 2010Review
- Estrogen coordinates translation and transcription, revealing a role for NRSF in human breast cancer cells.Molecular endocrinology (Baltimore, Md.) · 2010Article
- Anti-cancer therapies that utilize cell penetrating peptides.Recent patents on anti-cancer drug discovery · 2010Review
- Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.Nature cell biology · 2009Article
- Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.Journal of oncology · 2009Article
- Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2008Review
- Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.BMC cancer · 2006Article
- Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis.World journal of gastroenterology · 2006Review
- High eIF4E, VEGF, and microvessel density in stage I to III breast cancer.Annals of surgery · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveA previous study of patients with stage I to III breast cancer showed that those patients whose tumors were in the highest tertile of eIF4E overexpression experienced a higher risk for recurrence. This study was designed to determine whether high eIF4E overexpression predicts cancer recurrence independent of nodal status by specifically targeting patients with node-positive disease.
methodsThe prospective trial was designed to accrue 168 patients with node-positive breast cancer to detect a 2.5-fold increase in risk for recurrence. eIF4E level was quantified by Western blots as x-fold elevated compared with breast tissues from noncancer patients. End points measured were disease recurrence and cancer-related death. Statistical analyses performed include survival analysis by the Kaplan-Meier method, log-rank test, and Cox proportional hazard model.
resultsOne hundred seventy-four patients with node-positive breast cancer were accrued. All patients fulfilled study inclusion and exclusion criteria, treatment protocol, and surveillance requirements, with a compliance rate >95%. The mean eIF4E elevation was 11.0 +/- 7.0-fold (range, 1.4-34.3-fold). Based on previously published data, tertile distribution was as follow: 1) lowest tertile (<7.5-fold) = 67 patients, 2) intermediate tertile (7.5-14-fold) = 54 patients, and 3) highest tertile (>14-fold) = 53 patients. At a median follow up of 32 months, patients with the highest tertile had a statistically significant higher cancer recurrence rate (log-rank test, P = 0.002) and cancer-related death rate (P = 0.036) than the lowest group. Relative risk calculations demonstrated that high eIF4E patients had a 2.4-fold increase in relative risk increase for cancer recurrence (95% confidence interval, 1.2-4.1; P = 0.01).
conclusionsIn this prospective study designed to specifically address risk for recurrence in patients with node-positive breast cancer, the patients whose tumors were in the highest tertile of eIF4E overexpression had a 2.4-fold increase in relative risk for cancer recurrence. Therefore, eIF4E overexpression appears to be an independent predictor of a worse outcome in patients with breast cancer independent of nodal status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.